Stay updated on Duvelisib in Refractory Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.

Latest updates to the Duvelisib in Refractory Lymphoma Clinical Trial page
- Check2 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed; no substantive changes to core content.SummaryDifference0.2%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check16 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations, while removing several previous location entries and related medical topics.SummaryDifference3%
- Check23 days agoChange DetectedThe page has removed a significant study reference regarding Duvelisib in patients with refractory indolent non-Hodgkin lymphoma, which may impact the information available to readers about this treatment option.SummaryDifference0.4%
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11.SummaryDifference0.1%
Stay in the know with updates to Duvelisib in Refractory Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.